Patient Derived Xenografted Models

Leveraging its wealth of information on more than 400 fully characterized proprietary patients derived xenografts (PDX) in the portfolio, Creative Biolabs is dedicated to helping scientists in immuno-oncology research and providing the most appropriate PDX models for pre-clinical testing.

Our PDX Model Portfolio

Patient derived xenografted (PDX) models.

Our PDX models offer extensive backgrounds/characterization and represent almost all tissue types and cancer types. Over 400 PDX models are available to engraft into immunocompromised mice and humanized mice and ship to your facility or to use in preclinical testing studies guided by Creative Biolabs. Our PDX model portfolio includes:

✔ Various xenografted models including subcutaneous, orthotopic and disseminated models;
✔ Extensive background on patients’ treatment and molecular/pharmacological characterization;
✔ Corresponding CDX models available;
✔ One-stop platform from animal models to in vivo efficacy studies;
✔ Identification and analysis of biomarkers of in-house PDX models;
✔ PDX models using immunocompromised mice or humanized mice.

New PDX models are still being developed through continuous collaborations with major hospitals.

Our PDX Collections

Our well-characterized PDX models support the pre-clinical immuno-oncology research of more than 30 cancer types including rare indications and highly-specific molecular targets. For detailed collection information, please contact us.

■ ALL	■ AML	■ Adrenal	■ Bladder	■ Brain	■ Breast
■ Cervical	■ Cholangiocarcinoma	■ Colorectal	■ Esophageal	■ Fallopian	■ Gallbladder
■ Gastric	■ GIST	■ Head and neck	■ Kidney	■ Liver	■ Lung
■ Lymphoma	■ Melanoma	■ Mesothelioma	■ Mixed mullerian	■ Ovarian	■ Pancreatic
■ Peritoneal	■ Prostate	■ Sarcoma	■ Testis	■ Thyroid	■ Uterine

PDX models for specific molecular targets such as RET, ALK, EGFR, MET, IDH, RSPO, HER2, etc. are also available for your choice to fit your research.

Highlights

Our PDX models are established at low passage numbers, which can ensure the preservation of primitive tumor features such as clinical biomolecular signature, heterogeneous histology, malignant phenotypes and genotypes, and tumor vascular system and structure. Therefore, our PDX models are believed to be able to offer relevant predictive insights of clinical outcomes when evaluating preclinical in vivo efficacy of novel therapies.

Our scientists can assist in selecting the most appropriate PDX model to fit your therapy type and cancer type. Customized PDX models are also available upon request. Creative Biolabs is committed to facilitating your preclinical in vivo studies with PDX models at your fingertips, please contact us for detailed information, and we look forward to working with you.

For Research Use Only | Not For Clinical Use